List I | List II | ||
|---|---|---|---|
| A. | Voglibose | I. | AMP Activator |
| B. | Metformin | II. | K Channel blockers |
| C. | Tolbutamide | III. | \(\alpha\)-glucosidase Inhibitor |
| D. | Pioglitazone | IV. | PPAR-\(\gamma\) (gamma) activators |
List I | List II | ||
|---|---|---|---|
| A. | Aminoglycosides | I. | Hearing loss, kidney damage |
| B. | Tetracyclines | II. | Neurological and renal toxicity |
| C. | Vancomycin | III. | 8th cranial nerve and kidney toxicity |
| D. | Polymyxin B | IV. | Liver and kidney damage, anti anabolic effect |
List I | List II | ||
|---|---|---|---|
| A. | Aminoglycosides | I. | Hearing loss, kidney damage |
| B. | Tetracyclines | II. | Neurological and renal toxicity |
| C. | Vancomycin | III. | 8th cranial nerve and kidney toxicity |
| D. | Polymyxin B | IV. | Liver and kidney damage, anti anabolic effect |
List I | List II | ||
|---|---|---|---|
| A. | Lamivudine | I. | Integrase inhibitors |
| B. | Efavirenz | II. | Protease inhibitors |
| C. | Ritonavir | III. | Nucleoside reverse transcriptase inhibitors |
| D. | Raltegravir | IV. | Non-nucleoside reverse transcriptase inhibitors. |
List I | List II | ||
|---|---|---|---|
| A | Newtonian fluids | I | Dispersion containing high concentration of small deflocculated particle |
| B | Plastic flow | II | Water |
| C | Pseudoplastic flow | III | Concentrated suspension |
| D | Dilatant flow | IV | Aqueous dispersions of hydrocolloids |